俄罗斯在中国取得“优异成果”后尝试使用抗病毒药物法维拉韦作为冠状病毒治疗
在中国取得“优异成果”之后，俄罗斯准备测试抗病毒药物法维拉韦作为治疗COVID-19的药物。
俄罗斯在中国取得“优异成果”后尝试使用抗病毒药物法维拉韦作为冠状病毒治疗
在中国取得“优异成果”之后，俄罗斯准备测试抗病毒药物法维拉韦作为治疗COVID-19的药物。
国营的塔斯社周二报道，首批药物有望在一周内到货。
法维拉韦也正在其他国家（包括中国和中东）作为抗新型冠状病毒的潜在疗法进行测试。
在俄罗斯，俄罗斯主权财富基金俄罗斯直接投资基金（Russian Direct Investment Fund）首席执行官基里尔·德米特里耶夫（Kirill Dmitriev）表示，政府正在与ChemRar Group合作投资Favipiravir。
In an interview with Russia’s Channel One,
Dmitriev added:
“Together with the ChemRar Group, we are investing into a medicine that showed excellent results in China, and the first batch will arrive in one week.”
The U.S.
is also believed to have expressed interest in Favipiravir. According to a report in Politico at the end of March,
the Trump administration
is pushing for the Food and Drugs Administration (FDA) to grant emergency authorization for its use.
An FDA spokesperson
told Politico they could not comment on whether the agency would issue an emergency use authorization for the drug.
Test batch of antiviral drug Favipiravir to hit shelves in Russia next week
https://www.google.co.jp/amp/s/tass.com/world/1141035/amp
Russia’s RDIF backs ChemRar for the production of favipiravir against